Mizuho downgraded Kala Bio (KALA) to Neutral from Outperform with a price target of $1.50, down from $30. The firm cites yesterday’s negative Phase 2 results for the company’s lead asset KPI-012 for the downgrade. Mizuho is “very disappointed” by the data and has been unable to connect with management. The analyst removed KPI-012 Kala’s model and downgraded the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA: